Y. Bao

Tislelizumab Plus Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer (RATIONALE 304): A Randomized Phase 3 Trial.

Yunpeng Liu, Dong Wang, Jie Wang, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Tislelizumab in Asian patients with previously treated locally advanced or metastatic urothelial carcinoma

S. Park, Lilin Zhang, Jiyan Liu, 2020, Cancer science.

Examining the Impact of Tislelizumab Added to Chemotherapy on Health-Related Quality-of-Life Outcomes in Previously Untreated Patients With Nonsquamous Non–Small Cell Lung Cancer

Shun Lu, Yan Yu, B. Tang, 2022, Cancer journal.

The effects of tislelizumab plus chemotherapy as first-line treatment on health-related quality of life of patients with advanced squamous non-small cell lung cancer: Results from a phase 3 randomized clinical trial.

J. Wang, S. Leaw, Y. Bao, 2021, Cancer treatment and research communications.

Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study.

M. Ducreux, H. Chang, E. Chen, 2023, The Lancet. Oncology.

1263P Tislelizumab + chemotherapy vs chemotherapy alone as first-line treatment for locally advanced/metastatic nonsquamous NSCLC

Yunpeng Liu, Dong Wang, Juxian Wang, 2020 .